Phost’in Therapeutics Is Awarded €3.2m Through The France 2030 Investment Plan To Pioneer N-Glycosylation Inhibitors Against Chronic Fibrosis

Montpellier, France – September 2025, 8th

Phost’in Therapeutics SAS (Montpellier, France), a clinical-stage biotechnology company specialized in the discovery and development of N-glycosylation inhibitors for the treatment of cancer and other serious diseases; announced today that it has been selected as a laureate of the national I-DEMO Call for Projects to accelerate the development of its GlyPANASH program targeting chronic fibrosis. Phost’in will receive €3.2 million in non-dilutive funding through the France 2030 Plan, managed by Bpifrance on behalf of the French government.